Overview

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer

Status:
RECRUITING

Trial end date:
2028-12-30

Target enrollment:

Participant gender:

Summary

This is an exploratory and prospective study, with the research subjects being patients with initially untreated and unresectable biliary tract tumors. The efficacy and safety of the treatment regimen consisting of Adebrelimab monoclonal antibody combined with targeted therapy and systemic chemotherapy were investigated.

Phase:

PHASE2

Details

Lead Sponsor:

Yongjun Chen

Treatments:

apatinib